6 results about "FOXM1" patented technology

A pharmaceutical composition for preventing, ameliorating, or treating cancer, the pharmaceutical composition comprising an FOXM1 inhibitor and an immune checkpoint inhibitor as active ingredients. The FOXM1 inhibitor inhibits the expression of PD-L1 in a cell membrane and inhibits the translocation of FOXM1 to the nucleus, thereby reducing the proliferation and survival of cancer cells and inducing an increase in cell death, and thus has the effect of preventing, ameliorating, or treating cancer. In addition, when the FOXM1 inhibitor is administered in combination with an immune checkpoint inhibitor, tumor growth is inhibited more effectively than when the FOXM1 inhibitor or immune checkpoint inhibitor is used alone. Thus, the pharmaceutical composition can be useful as an agent for preventing or treating cancer.

The present application relates to a kind of FOXM1 protein phosphorylation modification interfering peptide and its application, belong to the field of biological medicine technology. Specifically, the present application is found in research, the transcriptional activity of FOXM1 protein depends on the condensate formed by its polymerization, destroying the polymerization of FOXM1 can effectively inhibit the occurrence and development of tumor, and the phosphorylation of the 376th amino acid of FOXM1 protein can also inhibit polymerization to some extent, thereby inhibiting the transcriptional activation of FOXM1 protein. Therefore, the present application designs an interfering peptide, and introduces phosphorylation modification in appropriate position, obtains a kind of phosphorylation modification interfering peptide FIP4 targeted to FOXM1 protein polymerization domain, the interfering peptide plays a significant role in inhibiting the transcriptional activation of FOXM1 protein in cell and animal in vivo, and can be used for treating tumor-related diseases.

A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.

The present application relates to the technical field of medicine, in particular to the use of a substance specifically binding to KLK8 in the preparation of a product for the prevention, treatment or diagnosis of sepsis, which treats sepsis by: 1) reducing endothelial cell permeability or improving capillary leakage; 2) stimulating the VE-cadherin / Akt / FOXM1 signaling pathway; preferably, selected from up-regulating the expression level of FOXM1 and its downstream target genes, up-regulating the protein level of AKT or p-AKT, or up-regulating the protein level of VE-cadherin; 3) increasing the proliferation rate of endothelial cells; 4) reducing the mortality rate of endothelial cells; 5) increasing the activity of endothelial cells. The present application provides a new treatment strategy for sepsis complicated with microvascular barrier dysfunction.

This invention discloses a combined application of FOXM1 inhibitor and BUB1 inhibitor, which has significant anti-tumor effects, synergistic effects and low toxicity. It is particularly suitable for the treatment of liver cancer, triple-negative breast cancer and melanoma, and solves the problems of poor efficacy, narrow indications, easy drug resistance and easy recurrence of monotherapy, providing a new strategy for tumor treatment.

The present invention relates to a diagnostic biomarker composition for PARP inhibitor response and a pharmaceutical composition for cancer treatment, including at least one miRNA selected from the group consisting of exosomal miR-664a-5p, miR-98-5p, and miR-95-3p as an active ingredient. The biomarker of the present invention can predict the therapeutic responsiveness and prognosis of cancer patients to PARP inhibitors, enabling the early identification of patients in whom the efficacy of PARP inhibitors is limited due to the development of resistance. Additionally, it has been confirmed that the biomarker of the present invention directly targets FOXM1, a transcription factor involved in chemotherapy resistance, to enhance sensitivity to PARP inhibitors. This finding demonstrates that the differential expression of the biomarker of the present invention plays a crucial role in regulating the efficacy of PARP inhibitors. Furthermore, the biomarker of the present invention can be identified as a potential therapeutic target for PARP inhibitor response in cancer patients.Accordingly, the biomarker of the present invention, either alone or in combination with a PARP inhibitor, can be effectively utilized for the treatment, prevention, and improvement of cancer.